These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 9633682)

  • 1. Initiating therapy for Parkinson's disease.
    Silver DE; Ruggieri S
    Neurology; 1998 Jun; 50(6 Suppl 6):S18-22; discussion S44-8. PubMed ID: 9633682
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of immediate-release and controlled release carbidopa/levodopa in Parkinson's disease. A multicenter 5-year study. The CR First Study Group.
    Block G; Liss C; Reines S; Irr J; Nibbelink D
    Eur Neurol; 1997; 37(1):23-7. PubMed ID: 9018028
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of Concomitant Medications on the Safety and Efficacy of Extended-Release Carbidopa-Levodopa (IPX066) in Patients With Advanced Parkinson Disease: A Post Hoc Analysis.
    LeWitt PA; Verhagen Metman L; Rubens R; Khanna S; Kell S; Gupta S
    Clin Neuropharmacol; 2018; 41(2):47-55. PubMed ID: 29432286
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Amantadine-induced "vocal" myoclonus.
    Pfeiffer RF
    Mov Disord; 1996 Jan; 11(1):104-6. PubMed ID: 8771080
    [No Abstract]   [Full Text] [Related]  

  • 5. The effect of anticholinergic drugs on cognition of patients with Parkinson's disease: a cohort study from the Egyptian population.
    Hamed SA; Hadad AFE
    Expert Rev Clin Pharmacol; 2024 Aug; 17(8):743-753. PubMed ID: 38781022
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of tolcapone in Parkinson's patients taking L-dihydroxyphenylalanine/carbidopa and selegiline.
    Davis TL; Roznoski M; Burns RS
    Mov Disord; 1995 May; 10(3):349-51. PubMed ID: 7651456
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effects of early selegiline therapy on long-term levodopa treatment and parkinsonian disability: an interim analysis of a Norwegian--Danish 5-year study. Norwegian-Danish Study Group.
    Larsen JP; Boas J
    Mov Disord; 1997 Mar; 12(2):175-82. PubMed ID: 9087975
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Strategies in the treatment of early Parkinson's disease.
    Rinne UK
    Acta Neurol Scand Suppl; 1993; 146():50-3. PubMed ID: 8101417
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The use of Stalevo in Hungary for patients with Parkinson disease and its effect on the quality of life].
    Klivényi P; Vécsei L
    Ideggyogy Sz; 2008 Jan; 61(1-2):42-8. PubMed ID: 18372774
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-dose pergolide monotherapy in the treatment of severe levodopa-induced dyskinesias.
    Facca A; Sanchez-Ramos J
    Mov Disord; 1996 May; 11(3):327-9. PubMed ID: 8723153
    [No Abstract]   [Full Text] [Related]  

  • 11. [High dosage therapy of Parkinson disease. New dopamine agonist pramipexol allows reduction of L-dopa dose down to zero].
    Arnold G; Kupsch A
    Nervenarzt; 1999 Aug; 70(8):742-4. PubMed ID: 10483575
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-Term Treatment with Extended-Release Carbidopa-Levodopa (IPX066) in Early and Advanced Parkinson's Disease: A 9-Month Open-Label Extension Trial.
    Waters CH; Nausieda P; Dzyak L; Spiegel J; Rudzinska M; Silver DE; Tsurkalenko ES; Kell S; Hsu A; Khanna S; Gupta S
    CNS Drugs; 2015 Apr; 29(4):341-50. PubMed ID: 25895021
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Implications of the 5-year CR FIRST trial. Sinemet CR Five-Year International Response Fluctuation Study.
    Capildeo R
    Neurology; 1998 Jun; 50(6 Suppl 6):S15-7; discussion S44-8. PubMed ID: 9633681
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drugs for Parkinson's disease.
    Treat Guidel Med Lett; 2013 Nov; 11(135):101-6. PubMed ID: 24165688
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Levodopa + carbidopa + entacapone. Entacapone: a second look: new preparations. Parkinson's disease: a modest effect.
    Prescrire Int; 2005 Apr; 14(76):51-4. PubMed ID: 15875340
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adjuncts to levodopa therapy: dopamine agonists.
    Poewe W
    Neurology; 1998 Jun; 50(6 Suppl 6):S23-6; discussion S44-8. PubMed ID: 9633683
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Prevention and treatment of fluctuations in patients with Parkinson's disease].
    Ludin HP; Surber Ch
    Praxis (Bern 1994); 2006 Dec; 95(51-52):2013-8. PubMed ID: 17294589
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Continuous duodenal infusions of levodopa.
    Fowler SB; Bergen M
    J Neurosci Nurs; 1993 Oct; 25(5):317-20. PubMed ID: 8270813
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The need for levodopa as an end point of Parkinson's disease progression in a clinical trial of selegiline and alpha-tocopherol. Parkinson Study Group.
    LeWitt P; Oakes D; Cui L
    Mov Disord; 1997 Mar; 12(2):183-9. PubMed ID: 9087976
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A multicenter double-blind placebo-controlled trial of pergolide as an adjunct to Sinemet in Parkinson's disease.
    Olanow CW; Fahn S; Muenter M; Klawans H; Hurtig H; Stern M; Shoulson I; Kurlan R; Grimes JD; Jankovic J
    Mov Disord; 1994 Jan; 9(1):40-7. PubMed ID: 8139604
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.